Ketamine for Combined Depression and Alcohol Use Disorder: A Blinded Randomized Active Placebo-controlled Trial (the KeDA Trial)
The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.
- Status
- recruiting
- Phase
- Phase 1, Phase 2
- Institution
- University Hospital of North Norway
- Principal investigator
- Ole K Grønli, Assoc Prof
- Start date
- 2025-01-20
- End date
- 2027-07-01
- Registry ID
- NCT06090422
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.